Ladostigil: A novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment

Current Drug Targets

Volumn 13, Issue 4, 2012, Pages 483-494

  Weinreb, Orly ^a   Amit, Tamar ^a   Bar Am, Orit ^a   Youdim, Moussa B H ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Yonsei University   (South Korea)

Author keywords

Alzheimer's disease; Cholinesterase inhibitor; Monoamine oxidase inhibitor; Multifunctional drug; Neuroprotection

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; 6 HYDROXYRASAGILINE; AMINE OXIDASE (FLAVIN CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMITRIPTYLINE; AMYLOID PRECURSOR PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CLORGYLINE; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HOMOVANILLIC ACID; HYDROXY 1 AMINOINDAN; INDAN DERIVATIVE; LADOSTIGIL; MESSENGER RNA; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; RASAGILINE; REACTIVE OXYGEN METABOLITE; RIVASTIGMINE; SCOPOLAMINE; SELEGILINE; SEROTONIN; STREPTOZOCIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIDEPRESSANT ACTIVITY; APOPTOSIS; BRAIN; BRAIN FUNCTION; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHOLINESTERASE INHIBITION; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; GLIOSIS; HIPPOCAMPUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEMORY DISORDER; MONOTHERAPY; NEUROBLASTOMA CELL; NEUROPATHOLOGY; NEUROPHARMACOLOGY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONISM; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; SYMPTOM; TREATMENT OUTCOME; WORKING MEMORY;

ALZHEIMER DISEASE; ANIMALS; BRAIN; CHOLINESTERASE INHIBITORS; HUMANS; INDANS; LEWY BODY DISEASE; MICE; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; RATS; SIGNAL TRANSDUCTION;

EID: 84857709982     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012799499794     Document Type: Review

References (144)

1. Bullock R. Future directions in the treatment of Alzheimer's disease. Expert Opin Investig Drugs 2004; 13: 303-14.
2. Eckert A, Keil U, Marques CA, et al. Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. Biochem Pharmacol 2003; 66: 1627-34.
3. Maccioni RB, Munoz JP, Barbeito L. The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch Med Res 2001; 32: 367-81.
4. Tsolaki M, Kokarida K, Iakovidou V, Stilopoulos E, Meimaris J, Kazis A. Extrapyramidal symptoms and signs in Alzheimer's disease: prevalence and correlation with the first symptom. Am J Alzheimers Dis Other Demen 2001; 16: 268-78.
5. Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003; 43: 545-84.
6. Schliebs R. Basal forebrain cholinergic dysfunction in Alzheimer's disease--interrelationship with beta-amyloid, inflammation and neurotrophin signaling. Neurochem Res 2005; 30: 895-08.
7. Palmer AM, Stratmann GC, Procter AW, Bowen DM. Possible neurotransmitter basis of behavioral changes in Alzheimer's disease. Ann Neurol 1988; 23: 616-20.
8. Newman SC. The prevalence of depression in Alzheimer's disease and vascular dementia in a population sample. J Affect Disord 1999; 52: 169-76.
9. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T. Drug Class Review on Alzheimer's Drugs: Final Report Portland (OR): Oregon Health & Science University 2006.
10. Greenamyre JT, Maragos WF, Albin RL, Penney JB, Young AB. Glutamate transmission and toxicity in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12: 421-30.
11. Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol. 1991; 206: 297-300.
12. Lleo A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer's disease. Annu Rev Med 2006; 57: 513-33.
13. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999; 66: 137-47.
14. Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002; 72: 310-14.
15. Giacobini E. Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer' disease. J Neural Transm 2002; suppl 62: 181-87.
16. Racchi M, Mazzucchelli M, Porrello E, Lanni C, Govoni S. Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacol Res 2004; 50: 441-51.
17. Francis PT, Nordberg A, Arnold SE. A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease? Trends Pharmacol Sci 2005; 26: 104-11.
18. Akasofu S, Kimura M, Kosasa T, Sawada K, Ogura H. Study of neuroprotection of donepezil, a therapy for Alzheimer's disease. Chem Biol Interact 2008; 175: 222-26.
19. Arias E, Ales E, Gabilan NH, et al. Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology 2004; 46: 103-14.
20. Bailey JA, Lahiri DK. A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease. J Neurochem 2010; 112: 843-53.
21. Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Sugimoto H, Akaike A. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology 2006; 51: 474-86.
22. Clark CM, Karlawish JH. Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. Ann Intern Med 2003; 138: 400-10.
23. Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J. Therapeutic approaches to Alzheimer's disease. Brain 2006; 129: 2840-55.
24. Rogers JT, Lahiri DK. Metal and inflammatory targets for Alzheimer's disease. Curr Drug Targets 2004; 5: 535-51.
25. Joseph JA, Shukitt-Hale B, Casadesus G, Fisher D. Oxidative stress and inflammation in brain aging: nutritional considerations. Neurochem Res 2005; 30: 927-35.
26. Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G. Oxidative stress in Alzheimer's disease. Biochimica et biophysica acta 2000; 1502: 139-44.
27. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317-24.
28. Van der Schyf CJ, Gal S, Geldenhuys WJ, Youdim MB. Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases. Expert Opin Investig Drugs 2006; 15: 873-86.
29. Sabbagh MN, Farlow MR, Relkin N, Beach TG. Do cholinergic therapies have disease-modifying effects in Alzheimer's disease? Alzheimers Dement 2006; 2: 118-25.
30. Weinstock M, Bejar C, Wang RH, et al. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J Neural Transm 2000; [Suppl] 60: S157-S70.
31. Weinstock M, Kirschbaum-Slager N, Lazarovici P, Bejar C, Youdim MBH, Shoham S. Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. Ann N Y Acad Sci 2001; 939: 148-61.
32. Weinstock M, Goren T, Youdim MBH. Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimer's disease, with cholinesterase and monoamine oxidase inhibitory activities. Drug Dev Res 2000; 50: 216-22.
33. Sterling J, Herzig Y, Goren T, et al. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J Med Chem 2002; 45: 5260-79.
34. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002; 59: 1937-43.
35. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004; 61: 561-66.
36. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005; 62: 241-48.
37. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268-78.
38. Chen JJ, Swope DM. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol 2005; 45: 878-94.
39. Weinreb O, Amit T, Bar-Am O, Youdim MB. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol 2010; 92: 330-44.
40. Sagi Y, Mandel S, Amit T, Youdim MB. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol Dis 2007; 25: 35-44.
41. Heikkila RE, Duvoisin RC, Finberg JP, Youdim MBH. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur J Pharmacol 1985; 116: 313-17.
42. Speiser Z, Mayk A, Eliash S, Cohen S. Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J Neural Transm 1999; 106: 593-606.
43. Eliash S, Speiser Z, Cohen S. Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats. J Neural Transm 2001; 108: 909-23.
44. Huang W, Chen Y, Shohami E, Weinstock M. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol 1999; 366: 127-35.
45. Zhu W, Xie W, Pan T, et al. Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neurochem 2008; 105: 1970-78.
46. Abu-Raya S, Blaugrund E, Trembovler V, Shilderman-Bloch E, Shohami E, Lazarovici P. Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-different PC12 cells against oxygen-glucose deprivation. J Neurosci Res 1999; 58: 456-63.
47. Weinreb O, Bar-Am O, Amit T, Chillag-Talmor O, Youdim MBH. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J 2004; 18: 1471-73.
48. Tatton WG, Chalmers-Redman RM, Ju WJ, et al. Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J Pharmacol Exp Ther 2002; 301: 753-64.
49. Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MB, Naoi M. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 2002; 24: 675-82.
50. Maruyama W, Akao Y, Youdim MB, Davis BA, Naoi M. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J Neurochem 2001; 78: 727-35.
51. Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MBH, Naoi M. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett 2002; 326: 105-08.
52. Akao Y, Maruyama W, Shimizu S, et al. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl- 2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem 2002; 82: 913-23.
53. Maruyama W, Akao Y, Youdim MBH, Naoi M. Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine- 1(R)- and (S)-aminoindan, rasagiline and TV1022. J Neural Transm 2000; Suppl 60: 171-86.
54. Maruyama W, Youdim MBH, Naoi M. Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. Ann N Y Acad Sci 2001; 939: 320-29.
55. Maruyama W, Takahashi T, Youdim MBH, Naoi M. The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm 2002; 109: 467-81.
56. Ou XM, Lu D, Johnson C, et al. Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res 2009; 16: 148-59.
57. Ou XM, Stockmeier CA, Meltzer HY, et al. A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage Biol Psychiatry 2010; 67: 855-63.
58. Finberg JP, Lamensdorf I, Weinstock M, Schwartz M, Youdim MBH. Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol 1999; 80: 495-99.
59. Bar-Am O, Yogev-Falach M, Amit T, Sagi Y, M.B.H Y. Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J Neurochem 2004; 89: 1119-25.
60. Bar-Am O, Weinreb O, Amit T, Youdim MB. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J 2005; 19: 1899-901.
61. Yogev-Falach M, Amit T, Bar-am O, Youdim MBH. The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing. FASEB J 2003; 17: 2325-27.
62. Maycock AL, Abeles RH, Salach JI, Singer TP. The structure of the covalent adduct formed by the interaction of 3-dimethylamino-1-propyne and the flavine of mitochondrial amine oxidase. Biochemistry 1976; 15: 114-25.
63. Youdim MBH, Gross A, Finberg JPM. Rasagiline [N-Propargyl-1R(+)-aminoindant], A selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 2001; 132: 500-06.
64. Maruyama W, Yamamoto T, Kitani K, Carrillo MC, Youdim MBH, Naoi M. Mechanism underlying anti-apoptotic activity of a (-) deprenyl-related propargylamine, rasagiline. Mech Ageing Dev 2000; 116: 181-91.
65. Yogev-Falach M, Amit T, Bar-Am O, Sagi Y, Weinstock M, Youdim MBH. The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J 2002; 16: 1674-76.
66. Weinstock M, Razin M, Chorev M, Enz A. Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors. J Neural Transm 1994; 43: 219-25.
67. Machado JC. Review: rivastigmine reduces rate of cognitive decline and improves performance in mild to moderate Alzheimer's. Evid Based Ment Health. 2009; 12: 113.
68. Farlow MR. Update on rivastigmine. Neurologist 2003; 9: 230-34.
69. Leber P. Observations and suggestions on antidementia drug development. Alzheimer Dis Assoc Disord 1996; 10 Suppl 1: 31-35.
70. Farlow M, Potkin S, Koumaras B, Veach J, Mirski D. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Arch Neurol 2003; 60: 843-48.
71. Weinstock M. Selectivity of cholinesterase inhibition: clinical implications for the treatment of Alzheimer's disease. CNS Drugs. 1999; 12: 307-23.
72. Cutler NR, Polinsky RJ, Sramek JJ, et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta Neurol Scand 1998; 97: 244-250.
73. Bejar C, Wang RH, Weinstock M. Effect of rivastigmine on scopolamine-induced memory impairment in rats. Eur J Pharmacol 1999; 383: 231-40.
74. Gauthier S, Vellas B, Farlow M, Burn D. Aggressive course of disease in dementia. Alzheimers Dement 2006; 2: 210-17.
75. Touchon J, Bergman H, Bullock R, Rapatz G, Nagel J, Lane R. Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology. Curr Med Res Opin 2006; 22: 49-59.
76. Giacobini E, Spiegel R, Enz A, Veroff AE, Cutler NR. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. J Neural Transm 2002; 109: 1053-65.
77. Arias E, Gallego-Sandin S, Villarroya M, Garcia AG, Lopez MG. Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. J Pharmacol Exp Ther 2005; 315: 1346-53.
78. Zhou X, Patel AR, Perez F, Jurivich DA. Acteylcholinesterase inhibitor rivastigmine enhances cellular defenses in neuronal and macrophage-like cell lines. Transl Res 2009; 153: 132-41.
79. Weinstock M, Gorodetsky E, Poltyrev T, Gross A, Sagi Y, Youdim MBH. A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 555-61.
80. Sagi Y, Drigues N, Youdim MB. The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats. Br J Pharmacol 2005; 146: 553-60.
81. Davis KL, Rosenberg GS. Induction of behavioral supersensitivity to apomorphine by DFP treatment. Life Sciences 1981; 28: 1953-59.
82. Rastogi SK, Rastogi RB, Singhal RL, Lapierre YD. Effects of cholinergic and GABAergic drugs on apomorphine-induced gnawing behavior in rats. Biol Psychiatry 1982; 17: 937-46.
83. Scali C, Casamenti F, Bellucci A, Costagli C, Schmidt B, Pepeu G. Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats. J Neural Transm 2002; 109: 1067-80.
84. Izzo PN, Bolam JP. Cholinergic synaptic input to different parts of spiny striatonigral neurons in the rat. J Comp Neurol 1988; 269: 219-34.
85. Calabresi P, Centonze D, Bernardi G. Electrophysiology of dopamine in normal and denervated striatal neurons. Trends Neurosci 2000; 23: S57-63.
86. Groner E, Ashani Y, Schorer-Apelbaum D, Sterling J, Herzig Y, Weinstock M. The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates. Mol Pharmacol 2007; 71: 1610-7.
87. Hubalek F, Binda C, Li M, et al. Inactivation of Purified Human Recombinant Monoamine Oxidases A and B by Rasagiline and Its Analogues. J Med Chem 2004; 25;47: 1760-66.
88. Sagi Y, Weinstock M, Youdim MBH. Attenuation of MPTP-Induced Dopaminergic Neurotoxicity by TV3326, A cholinesterase-monoamine oxidase inhibitor. J Neurochem 2003; 2: 290-97.
89. Weinstock M, Gorodetsky E, Wang RH, Gross A, Weinreb O, Youdim MBH. Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits. Neuropharmacology 2002; 43: 999-1005.
90. Weinstock M, Poltyrev T, Bejar C, Youdim MB. Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression. Psychopharmacology 2002; 160: 318-24.
91. Buccafusco JJ, Terry AV, Goren T, Blaugrun E. Potential cognitive actions of (n-propargly-(3r)-aminoindan-5-yl)-ethyl, methyl carbamate (TV3326), a novel neuroprotective agent, as assessed in old rhesus monkeys in their performance of versions of a delayed matching task. Neuroscience 2003; 119: 669-78.
92. Shoham S, Bejar C, Kovalev E, Schorer-Apelbaum D, Weinstock M. Ladostigil prevents gliosis, oxidative-nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats. Neuropharmacology 2007; 52: 836-43.
93. Luques L, Shoham S, Weinstock M. Chronic brain cytochrome oxidase inhibition selectively alters hippocampal cholinergic innervation and impairs memory: prevention by ladostigil. Exp Neurol 2007; 206: 209-19.
94. Weinreb O, Drigues N, Sagi Y, Reznick AZ, Amit T, Youdim MB. The application of proteomics and genomics to the study of age-related neurodegeneration and neuroprotection. Antioxid Redox Signal 2007; 9: 169-79.
95. Vetrivel KS, Thinakaran G. Amyloidogenic processing of beta-amyloid precursor protein in intracellular compartments. Neurology 2006; 66: S69-73.
96. Kern A, Roempp B, Prager K, Walter J, Behl C. Down-regulation of endogenous amyloid precursor protein processing due to cellular aging. J Biol Chem 2006; 281: 2405-13.
97. Maruyama W, Weinstock M, Youdim MB, Nagai M, Naoi M. Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)- (3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci Lett 2003; 341: 233-36.
98. Wadia JS, Chalmers-Redman RME, Ju WJH, et al. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor with drawal: time course and modification by (-)-deprenyl. J Neurosci 1998; 18: 932-47.
99. Bar-Am O, Weinreb O, Amit T, Youdim MB. The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats. J Mol Neurosci 2009; 37: 135-45.
100. Weinreb O, Bar-Am O, Amit T, Drigues N, Sagi Y, Youdim MB. The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity. Chem Biol Interact 2008; 175: 318-26.
101. Yogev-Falach M, Bar-Am O, Amit T, Weinreb O, Youdim MB. A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. FASEB J 2006; 20: 2177-79.
102. Sweatt JD. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem 2001; 76: 1-10.
103. Weinreb O, Amit T, Mandel S, Kupershmidt L, Youdim MB. Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities. Antioxid Redox Signal 2010; 13: 919-49.
104. Weinreb O, Amit T, Bar-Am O, Youdim MB. Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann N Y Acad Sci 2007; 1122: 155-68.
105. Siegel GJ, Chauhan NB. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res Brain Res Rev 2000; 33: 199-27.
106. Shen L, Figurov A, Lu B. Recent progress in studies of neurotrophic factors and their clinical implications. J Mol Med 1997; 75: 637-44.
107. Segal RA, Greenberg ME. Intracellular signaling pathways activated by neurotrophic factors. Annu Rev Neurosci 1996; 19: 463-89.
108. Murakami H, Iwashita T, Asai N, et al. Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation. Biochem Biophys Res Commun 1999; 262: 68-75.
109. Maruyama W, Naoi M, Youdim MBH. Propargylamines protect dopamine cells from apoptosis induced by a neurotoxin, N-Methyl (R) salsolinol. In: Alexander S, Gollins MA, Eds. Neuromelanin, May Mediate Neurotoxicity Via Its Interaction With Redox Active Iron. New York: Kluwer Academic/Plenum Publishers 2000: 321.
110. Mamelak M. Alzheimer' s disease, oxidative stress and gammahydroxybutyrate. Neurobiol Aging 2007; 28: 1340-60.
111. Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001; 60: 759-67.
112. Rhee SG, Kim KH, Chae HZ, et al. Antioxidant defense mechanisms: a new thiol-specific antioxidant enzyme. Ann N Y Acad Sci 1994; 738: 86-92.
113. Stone JR, Yang S. Hydrogen peroxide: a signaling messenger. Antioxid Redox Signal 2006; 8: 243-70.
114. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992; 59: 1609-23.
115. Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 2001; 18: 685-716.
116. Zhang L, Yu H, Sun Y, et al. Protective effects of salidroside on hydrogen peroxide-induced apoptosis in SH-SY5Y human neuroblastoma cells. Eur J Pharmacol 2007; 564: 18-25.
117. Schallreuter KU, Elwary S. Hydrogen peroxide regulates the cholinergic signal in a concentration dependent manner. Life Sci 2007; 80: 2221-26.
118. Xiao XQ, Lee NT, Carlier PR, Pang Y, Han YF. Bis(7)-tacrine, a promising anti-Alzheimer's agent, reduces hydrogen peroxide-induced injury in rat pheochromocytoma cells: comparison with tacrine. Neurosci Lett 2000; 290: 197-200.
119. Xiao XQ, Yang JW, Tang XC. Huperzine A protects rat pheochromocytoma cells against hydrogen peroxide-induced injury. Neurosci Lett 1999; 275: 73-76.
120. Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nature Rev 2006; 7: 295-309.
121. Carrillo MC, Minami C, Kitani K, et al. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci 2000; 67: 577-85.
122. Dragoni S, Porcari V, Travagli M, Castagnolo D, Valoti M. Antioxidant properties of propargylamine derivatives: assessment of their ability to scavenge peroxynitrite. J Pharm Pharmacol 2006; 58: 561-65.
123. Ba F, Pang PK, Benishin CG. The establishment of a reliable cytotoxic system with SK-N-SH neuroblastoma cell culture. J Neurosci Methods 2003; 123: 11-22.
124. Stringer JL, Gaikwad A, Gonzales BN, Long DJ, Marks LM, Jaiswal AK. Presence and induction of the enzyme NAD(P)H: quinone oxidoreductase 1 in the central nervous system. J Comp Neurol 2004; 471: 289-97.
125. Zafar KS, Inayat-Hussain SH, Siegel D, Bao A, Shieh B, Ross D. Overexpression of NQO1 protects human SK-N-MC neuroblastoma cells against dopamine-induced cell death. Toxicol Lett 2006; 166: 261-67.
126. SantaCruz KS, Yazlovitskaya E, Collins J, Johnson J, DeCarli C. Regional NAD(P)H: quinone oxidoreductase activity in Alzheimer's disease. Neurobiol Aging 2004; 25: 63-69.
127. Weinstock M, Luques L, Poltyrev T, Bejar C, Shoham S. Ladostigil prevents age-related glial activation and spatial memory deficits in rats. Neurobiol Aging 2011 32: 1069-78.
128. Liu R, Choi J. Age-associated decline in gamma-glutamylcysteine synthetase gene expression in rats. Free Radic Biol Med 2000; 28: 566-74.
129. Liu RM. Down-regulation of gamma-glutamylcysteine synthetase regulatory subunit gene expression in rat brain tissue during aging. J Neurosci Res 2002; 68: 344-51.
130. Zhu Y, Carvey PM, Ling Z. Age-related changes in glutathione and glutathione-related enzymes in rat brain. Brain Res 2006; 1090: 35-44.
131. Pakaski M, Kasa P. Role of acetylcholinesterase inhibitors in the metabolism of amyloid precursor protein. Curr Drug Targets CNS Neurol Disord 2003; 2: 163-71.
132. Bar-Am O, Amit T, Weinreb O, Youdim MB, Mandel S. Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of mitogen activated protein kinase and protein kinase C activation. J Alzheimers Dis 2010; 21: 361-71.
133. Zhang YW, Xu H. Molecular and cellular mechanisms for Alzheimer's disease: understanding APP metabolism. Curr Mol Med 2007; 7: 687-96.
134. Chen Y, Tang BL. The amyloid precursor protein and postnatal neurogenesis/neuroregeneration. Biochem Biophys Res Commun 2006; 341: 1-5.
135. Chow VW, Mattson MP, Wong PC, Gleichmann M. An overview of APP processing enzymes and products. Neuromolecular Med 2010; 12: 1-12.
136. Mills J, Reiner PB. Mitogen-activated protein kinase is involved in N-methyl-D-aspartate receptor regulation of amyloid precursor protein cleavage. Neuroscience 1999; 94: 1333-38.
137. Mills J, Reiner PB. Regulation of amyloid precursor protein cleavage. J Neurochem 1999; 72: 443-60.
138. Hung AY, Haass C, Nitsch RM, et al. Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. J Biol Chem 1993; 268: 22959-62.
139. Greig NH, Utsuki T, Yu Q, et al. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin 2001; 17: 159-65.
140. Sterling J, Veinberg A, Lerner D, et al. (R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. J Neural Transm Suppl 1998; 52: 301-05.
141. Bar-Am O, Amit T, Youdim MB. Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J Neurochem 2007; 103: 500-08.
142. Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 2005; 4: 71-78.
143. Hopkins AL, Mason JS, Overington JP. Can we rationally design promiscuous drugs? Curr Opin Struct Biol 2006; 16: 127-36.
144. Zheng H, Youdim MB, Fridkin M. Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy. ACS Chem Biol 2010; 5: 603-10.